Background: Patients show an elevated postprandial satiety gut hormone release after Roux-en-Y Gastric bypass (gastric bypass). The altered gut hormone response appears to have a prominent role in the reduction of appetite and body weight (BW) after gastric bypass. Patients with insufficient BW loss after gastric bypass have an attenuated postprandial gut hormone response in comparison with patients who lost an adequate amount of BW. The effects of additional gut hormone administration after gastric bypass are unknown. Methods: The effects of peripheral administration of peptide YY3-36 (PYY3-36; 300 nmol kg À1 ), glucagon-like peptide-1 (GLP-1) analogue Exendin-4 (20 nmol kg À1 ) and somatostatin analogue octreotide (10 mg kg À1 ) on feeding and BW were evaluated in rats after gastric bypass. Results: Gastric bypass rats weighed (Po0.01) and ate less on postoperative day 5 (Po0.001) and thereafter, whereas postprandial plasma PYY and GLP-1 levels were higher compared with sham-operated controls (Po0.001). Administration of both PYY3-36 and Exendin-4 led to a further decrease in food intake in bypass rats compared with saline treatment (P ¼ 0.02 and Po0.0001, respectively). Similar reduction in food intake was observed in sham rats (P ¼ 0.02 and Po0.001, respectively). Exendin-4 treatment resulted in a significant BW loss in bypass (P ¼ 0.03) and sham rats (P ¼ 0.04). Subsequent treatment with octreotide led to an increase in food intake in bypass (P ¼ 0.007), but not in sham rats (P ¼ 0.87). Conclusion: Peripheral administration of PYY3-36 and Exendin-4 reduces short-term food intake, whereas octreotide increases short-term food intake in rats after gastric bypass. The endogenous gut hormone response after gastric bypass can thus potentially be further enhanced by additional exogenous therapy with pharmacological doses of gut hormones in patients with insufficient weight loss or weight regain after surgery.
Introduction
The Roux-en-Y gastric bypass operation (gastric bypass) is one of the most effective therapeutic options currently available for significant and sustained weight loss, and has been shown to have a proven mortality benefit. 1 Although the surgery was initially designed to cause weight loss by alimentary restriction and malabsorption, it appears that the surgical manipulations also change the metabolic, gastrointestinal, hormonal and nervous system physiology. 2 The underlying mechanisms of surgically induced weight loss remain incompletely understood, 3 but they seem to induce a decrease in hunger, an increase in satiety, changes in food preferences and energy expenditure. 4 The first mechanisms have been shown to be at least partly physiologically induced by alterations in gastrointestinal and central neuroendocrine signalling. [5] [6] [7] [8] The postprandial responses of the gut hormones glucagonlike peptide-1 (GLP-1) and peptide YY3-36 (PYY), which are produced from the L cells in the gut, are increased after gastric bypass. [6] [7] [8] We and others have demonstrated in a rodent model that these anorexigenic gut hormones reduce hunger and induce satiety in a dose-dependent manner. 9, 10 We have also found that patients with suboptimal body weight (BW) loss after gastric bypass had attenuated postprandial PYY and GLP-1 responses. 6 Inhibition of the satiety gastrointestinal hormone response with the somatostatin analogue octreotide increased appetite and food intake in gastric bypass patients, 6 whereas specific antagonism of PYY increased food intake in gastric bypass rats. 8 A single peptide is unlikely to be responsible for all of the reported gastric bypass effects, as several satiety gut hormones are released in concert. The combined effect of exogenous peptide YY3-36 (PYY3-36) and GLP-1 (refs 11-13) as well as PYY3-36 and oxyntomodulin has been shown to amplify reductions in food intake in unoperated rats [11] [12] [13] and humans.
14 In this study, we investigated whether the single peripheral administration of the gut hormones PYY3-36 and Exendin-4 in pharmacological doses has an additional effect on food intake and BW after gastric bypass in rats. We also studied the effect of octreotide on food intake and BW in the same group of rats.
Materials and methods

Animals
The Home Office UK (PL 70-6669) approved all experiments of this study. In all, 22 obese male Wistar rats (BW 468.5±3.4 g) were individually housed under a 12 h/12 h light-dark cycle with lights on at 0700 hours. Room temperature was 21 ± 2 1C, and rats had ad libitum access to normal chow (RM1 diet, Special Diet Services Ltd, Essex, UK) and tap water unless otherwise stated. BW and food intake were measured daily for 60 days after surgery.
Gastric bypass surgery After 1 week of acclimatisation, rats were randomised and had gastric bypass or sham operation according to an established protocol as previously described. 15 Briefly, the proximal jejunum was divided 15 cm distal to the pylorus to create a biliopancreatic limb. After identification of the caecum, the ileum was followed proximally to create a common channel of 25 cm. Here a 7 mm side-to-side jejunojejunostomy between the biliopancreatic limb and the common channel was performed. The gastric pouch and alimentary limb were anastomosed end-to-side, and the gastric remnant was closed. Sham operations consisted of a 7 mm gastrostomy on the anterior wall of the stomach with subsequent closure and a 7 mm jejunostomy with subsequent closure.
Study design
The study was performed in a randomised, saline-controlled, crossover manner, with each animal treated once-off with three different compounds: PYY3-36 (300 nmol kg On the study day, both bypass and sham-operated rats were fasted from the onset of the light cycle at 0700 hours, and randomised into two groups receiving either vehicle (isotonic saline, Bayer, Newbury, UK) or one of the three compounds. All injections were administered intraperitoneal at 1 hour before the onset of the dark cycle. At the beginning of the dark cycle at 1900 hours, animals received ad libitum access to food and cumulative food intake was measured at 1, 2, 4, 8 and 12 h, and thereafter.
Hormone assays
Blood from all rats was collected on the day of study termination. Animals had ad libitum food access the night before and were decapitated at the beginning of the light cycle on postoperative day 60. Blood was obtained, immediately centrifuged at 3000 r.p.m. for 10 min at 4 1C, and stored at À20 1C until the samples were assayed in duplicate in a single run. PYY-like immunoreactivity was measured with a specific and sensitive radioimmunoassay, which measures, both the full length (PYY1-36) and the fragment (PYY3-36). 16, 17 GLP-1 was measured by established in-house radioimmunoassays.
18,19
Statistical analysis All data are expressed as mean±s.e.m. Two-way treatment (between subjects) Â time (within subjects) analysis of variance with post hoc bonferroni test for each time point was used to test for significant differences. Paired Student's t-test was used for independent samples. Po0.05 was considered significant. Figure 1a shows that the preoperative BW of sham-operated (469±5 g) and gastric bypass rats (468±5 g) was similar (P ¼ 0.84). After postoperative day 5, the BW of the gastric bypass rats (316 ± 7 g) was significantly lower than that of the sham-operated controls (345±6 g, Po0.01). Subsequent weight gain was constant among sham-operated rats, and on day 60 there was an approximate 180 g difference in BW between the two groups (day 60, sham: 573±9 g versus bypass: 394±7 g, Po0.01). Bypass rats demonstrated a lower daily food intake (27.4 ± 0.3 g) compared with sham-operated rats (30.5 ± 0.3 g, Po0.001; Figure 1b ). Feeding studies PYY3-36 administration. Figures 2a and b show the cumulative 12-h food intake after PYY3-36 injection for both groups of rats. Table 1 summarises the values of the two-way analysis of variances for food intake after PYY3-36 treatment. Sham-operated controls ate significantly less after PYY3-36 treatment than after saline treatment (P ¼ 0.02), whereas there was a significant main effect of time (Po0.001) and a significant time Â treatment interaction (Po0.001). PYY3-36 treatment reduced food intake in gastric bypass rats compared with saline treatment (P ¼ 0.02). There was also a significant main effect of time (Po0.001) and a significant time Â treatment interaction (P ¼ 0.001). The BW of shamoperated rats was 551.6 ± 12.6 g before and 552.8 ± 11.9 g after PYY3-36 treatment (P ¼ 0.4), whereas the BW of gastric bypass rats was 383.5 ± 11.1 g before and 374.6 ± 9.2 g after PYY3-36 treatment (P ¼ 0.2).
Results
BW and food intake
Exendin-4 administration. Figures 2c and d demonstrate the cumulative food intake after Exendin-4 injection. Table 1 summarises the values of two-way analysis of variances for food intake after Exendin-4 treatment for both groups. Exendin-4 treatment significantly reduced food intake in sham-operated rats in comparison with saline treatment (Po0.001). There was a significant main effect of time (Po0.001) and a significant time Â treatment interaction (Po0.001). Exendin-4 treatment also significantly reduced food intake in gastric bypass rats when compared with saline treatment (Po0.001), with a maximum effect between 4 and 8 h after injection. A significant main effect of time (Po0.001) and a significant time Â treatment interaction (P ¼ 0.001) were found. The BW of sham-operated rats was 565.3 ± 12.3 g before and 550.1 ± 12.1 g after Exendin-4 (P ¼ 0.041), whereas the BW of gastric bypass rats was 395.4 ± 8.9 g before and 370.9 ± 8.6 g after Exendin-4 (P ¼ 0.026). In both groups, the initial BW loss was regained within 48 h.
Octreotide treatment. Figures 2e and f show the cumulative 12 h food intake after octreotide administration. Table 1 summarises the values of two-way analysis of variances for food intake after octreotide treatment for both groups. Octreotide treatment had no effect on food intake of sham operated rats compared with saline (P ¼ 0.87), whereas a significant main effect of time was found (Po0.001), but without a significant time Â treatment interaction (P ¼ 0.22). In contrast, gastric bypass rats treated with octreotide ate significantly more than after saline injection (P ¼ 0.007). There was a significant main effect of time (Po0.001), but no time Â treatment interaction (P ¼ 0.16).
Clinical signs of malaise or distress (for example, piloerection, reduced activity or pica) were not observed after any of the three treatments.
Discussion
This study has demonstrated for the first time that pharmacological doses of gut hormones and gut hormone analogues PYY3-36 and Exendin-4 further reduced food intake after gastric bypass in rats. This short-term effect was observed even in the presence of the presumably increased levels of endogenous PYY3-36 and GLP-1. Inhibition of gut hormone responses with octreotide reversed the suppression of food intake seen after gastric bypass, resulting in a feeding behaviour comparable with that of shamoperated control rats. However, octreotide treatment did not affect food intake in sham-operated rats.
Increased endogenous secretion of gut hormones, such as PYY3-36 and GLP-1, is associated with reduced food intake after gastric bypass, whereas inhibition of gut hormone 
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Bypass + saline Bypass + Octreotide * * * Figure 2 Cumulative food intake in sham-operated rats (n ¼ 12, left column) and in gastric bypass rats (n ¼ 10, right column) after PYY3-36 (a, b), Exendin-4 (c, d) and octreotide treatment (e, f) in comparison with saline injections; data are shown as mean values ± s.e.m. Post hoc Bonferroni test was used for time to time analysis between the two treatment groups (*Po0.05, **Po0.01, ***Po0.001). The novel finding of this study is that food intake after gastric bypass can be altered by pharmacological doses of gut hormones or gut hormone analogues. This suggests that the increased endogenous PYY and GLP-1 levels after gastric bypass may not be at the top of the dose-response curve. The effects on food intake were pronounced after Exendin-4 administration and even led to a short-term reduction in BW.
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Our findings may have clinical implications. Postprandial PYY3-36 and GLP-1 levels are also elevated after gastric bypass in humans, 8 but the magnitude of the response can vary between patients and may be associated with differences in BW loss after surgery. 6 In fact, patients with a lower postoperative gut hormone response were demonstrated to achieve a lower BW loss after gastric bypass compared with patients with a more potent postprandial response of PYY and GLP-1.
6
Patients with poor BW loss or significant BW regain after surgery 28, 29 are currently left with limited therapeutic options. Surgical revision, including reduction of pouch size or lengthening of the Roux limb, 30 is frequently used despite the lack of supporting evidence in the literature. In addition, re-operations are associated with higher morbidity and mortality rates. 31 Effective and safe medical therapies could therefore become a valuable option in patients with poor weight loss or even regain of BW after bariatric surgery. The safety profile of supraphysiological levels of satiety gut hormones will need to be demonstrated first. Potential risks include hyperinsulinaemic hypoglycaemia as well as nausea and vomiting, which are the most common side effects observed with high doses of GLP-1 analogues. 32, 33 The underlying mechanisms causing pancreatic nesidioblastosis after gastric bypass [34] [35] [36] are currently unknown and only very few cases have been reported during the last 5 years, 34 suggesting that it is a rare complication of gastric bypass. However, cases of hyperinsulinaemic hypoglycaemia suggest a possible risk resulting from long-term stimulation of GLP-1 signalling, which must be considered before using high doses of GLP-1 in the long-term. Our study has certain limitations. First, the octreotide part of the study did not examine the selective inhibition of individual peptides on the regulation of food intake. However, we have previously shown that specific PYY3-36 antagonism using a purified PYY rabbit antibody increased food intake in gastric bypass rats. 8 Second, plasma gut hormone levels after treatment with octreotide were not measured, although octreotide has previously been shown to suppress PYY and GLP-1. 6, 37, 38 Third, even though a synergistic effect of PYY3-36 and GLP-1 analogues on reducing food intake has been demonstrated before, 39 it would have been intriguing to investigate the same effect after bypass surgery. Fourth, even though the animals did not show clinical signs of malaise or distress after the three treatment experiments, it was beyond the scope of this study to evaluate a conditional taste aversion, which may theoretically have contributed to the reduced food intake seen after PYY3-36 and Exendin-4. 40, 41 Finally, we did not perform a dose-response or an experiment to investigate the chronic effects of PYY3-36 and/or Exendin-4 administration on food intake and BW.
In conclusion, we have shown that single administration of PYY3-36 and Exendin-4 in pharmacological doses further decreased short-term food intake in a rat model of gastric bypass. This intervention is effective even in the presence of exaggerated anorexigenic peripheral signals after this form of obesity surgery. These findings will need to be translated to a clinical study in order to evaluate whether peripheral gut hormone treatment is a safe and effective therapeutic option in patients with insufficient BW loss or weight regain after gastric bypass.
